Sofinnova Investments
Menlo Park, CAfiles as Sofinnova Investments, Inc.
$1.9bn in 53 US stocks at the end of 30 June 2026. The top 10 are 59.8% of the money. It changed about 31.8% of the portfolio this quarter.
Value
$1.9bn
Stocks
53
Top 10 share
59.8%
Turnover
31.8%
What changed this quarter
New
Bought for the first time this quarter.
- Seaport TherapeuticsSPTX4.1% of the fund
- Gilead SciencesGILD2.3% of the fund
- Nurix TherapeuticsNRIX0.7% of the fund
- Design TherapeuticsDSGN0.7% of the fund
- First Tracks BiotherapeuticsTRAX0.6% of the fund
- Abbott LaboratoriesABT0.6% of the fund
- Sionna TherapeuticsSION0.3% of the fund
- AbsciABSI0.2% of the fund
- Sagimet BiosciencesSGMT<0.1% of the fund
- Aktis OncologyAKTS<0.1% of the fund
- HeartflowHTFL<0.1% of the fund
Added
Bought more of a stock they already held.
- Genmab A/SGMAB5.9% of the fund+438%
- Supernus PharmaceuticalsSUPN2.6% of the fund+9%
- AnaptysbioANAB1.8% of the fund+99%
- PharvarisPHVS1.6% of the fund+8%
- Arcus BiosciencesRCUS1.6% of the fund+2%
- VeradermicsMANE1.0% of the fund+103%
- Disc MedicineIRON0.6% of the fund+87%
- Tenax TherapeuticsTENX0.4% of the fund+379%
- OnKure TherapeuticsOKUR<0.1% of the fund+127%
Cut
Sold some of their stake.
- Jazz PharmaceuticalsJAZZ4.7% of the fund-39%
- Ultragenyx PharmaceuticalRARE3.1% of the fund-45%
- Bristol-Myers SquibbBMY2.7% of the fund-56%
- Rhythm PharmaceuticalsRYTM2.4% of the fund-9%
- United TherapeuticsUTHR2.2% of the fund-52%
- Cogent BiosciencesCOGT2.1% of the fund-51%
- Axsome TherapeuticsAXSM2.1% of the fund-25%
- IDEAYA BiosciencesIDYA1.8% of the fund-18%
- Nektar TherapeuticsNKTR1.8% of the fund-7%
- Inhibrx BiosciencesINBX1.5% of the fund-25%
- Biomarin PharmaceuticalBMRN1.1% of the fund-54%
- AlconALC0.9% of the fund-65%
- InsmedINSM0.9% of the fund-54%
- Definium TherapeuticsDFTX0.6% of the fund-26%
- Praxis Precision MedicinesPRAX0.1% of the fund-90%
- Tyra BiosciencesTYRA<0.1% of the fund-84%
Sold out
Sold their entire stake.
- AstrazenecaAZN-100%
- BiogenBIIB-100%
- CelcuityCELC-100%
- BridgeBio PharmaBBIO-100%
- DexcomDXCM-100%
- Xenon PharmaceuticalsXENE-100%
- StrykerSYK-100%
- Roivant SciencesROIV-100%
- Compass TherapeuticsCMPX-100%
- Oric PharmaceuticalsORIC-100%
- Tango TherapeuticsTNGX-100%
- AxogenAXGN-100%
- CytokineticsCYTK-100%
- Harmony Biosciences HoldingsHRMY-100%
- VaxcytePCVX-100%
- Establishment Labs HoldingsESTA-100%
- Acadia PharmaceuticalsACAD-100%
- Soleno Therapeutics-100%
- ZymeworksZYME-100%
Holdings
- Genmab A/SGMAB
- Share
- 5.9%
- Value
- $111m
- Shares
- 4,045,215
+438%
- Seaport TherapeuticsSPTX
- Share
- 4.1%
- Value
- $77m
- Shares
- 3,564,871
New
- First Tracks BiotherapeuticsTRAX
- Share
- 0.6%
- Value
- $11m
- Shares
- 565,199
New
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| NateraNTRA | 22.5% | $421m | 1,550,280 | Held |
| Vera TherapeuticsVERA | 6.4% | $120m | 2,793,987 | Held |
| Genmab A/SGMAB | 5.9% | $111m | 4,045,215 | +438% |
| Jazz PharmaceuticalsJAZZ | 4.7% | $88m | 365,341 | -39% |
| Rapport TherapeuticsRAPP | 4.2% | $79m | 1,904,408 | Held |
| Seaport TherapeuticsSPTX | 4.1% | $77m | 3,564,871 | New |
| ArriVent BioPharmaAVBP | 3.1% | $59m | 1,696,752 | Held |
| Ultragenyx PharmaceuticalRARE | 3.1% | $57m | 1,717,505 | -45% |
| BioAge LabsBIOA | 3.0% | $56m | 2,293,788 | Held |
| Bristol-Myers SquibbBMY | 2.7% | $51m | 876,970 | -56% |
| Supernus PharmaceuticalsSUPN | 2.6% | $48m | 1,036,328 | +9% |
| Rhythm PharmaceuticalsRYTM | 2.4% | $45m | 408,027 | -9% |
| Gilead SciencesGILD | 2.3% | $43m | 343,100 | New |
| United TherapeuticsUTHR | 2.2% | $41m | 76,489 | -52% |
| Cogent BiosciencesCOGT | 2.1% | $40m | 1,035,148 | -51% |
| Axsome TherapeuticsAXSM | 2.1% | $39m | 160,429 | -25% |
| ImmaticsIMTX | 2.0% | $37m | 3,669,346 | Held |
| Dyne TherapeuticsDYN | 2.0% | $37m | 1,658,384 | Held |
| ImmunomeIMNM | 1.9% | $36m | 1,720,316 | Held |
| IDEAYA BiosciencesIDYA | 1.8% | $34m | 925,119 | -18% |
| AnaptysbioANAB | 1.8% | $33m | 493,536 | +99% |
| Nektar TherapeuticsNKTR | 1.8% | $33m | 471,763 | -7% |
| PharvarisPHVS | 1.6% | $30m | 881,299 | +8% |
| Arcus BiosciencesRCUS | 1.6% | $29m | 945,690 | +2% |
| Inhibrx BiosciencesINBX | 1.5% | $29m | 303,103 | -25% |
| Biomarin PharmaceuticalBMRN | 1.1% | $21m | 358,568 | -54% |
| VeradermicsMANE | 1.0% | $18m | 148,993 | +103% |
| AlconALC | 0.9% | $17m | 255,824 | -65% |
| InsmedINSM | 0.9% | $17m | 158,398 | -54% |
| Edgewise TherapeuticsEWTX | 0.8% | $15m | 380,923 | Held |
| Nurix TherapeuticsNRIX | 0.7% | $13m | 524,098 | New |
| Design TherapeuticsDSGN | 0.7% | $13m | 865,135 | New |
| Definium TherapeuticsDFTX | 0.6% | $12m | 255,903 | -26% |
| First Tracks BiotherapeuticsTRAX | 0.6% | $11m | 565,199 | New |
| Abbott LaboratoriesABT | 0.6% | $11m | 122,998 | New |
| Disc MedicineIRON | 0.6% | $11m | 146,239 | +87% |
| Tenax TherapeuticsTENX | 0.4% | $7m | 500,039 | +379% |
| Sionna TherapeuticsSION | 0.3% | $6m | 144,432 | New |
| AbsciABSI | 0.2% | $4m | 337,400 | New |
| Mirum PharmaceuticalsMIRM | 0.2% | $3m | 27,591 | Held |
| Jade BiosciencesJBIO | 0.1% | $2m | 107,391 | Held |
| SavaraSVRA | 0.1% | $2m | 364,763 | Held |
| Praxis Precision MedicinesPRAX | 0.1% | $2m | 6,440 | -90% |
| SepternaSEPN | <0.1% | $2m | 47,506 | Held |
| OnKure TherapeuticsOKUR | <0.1% | $1m | 321,692 | +127% |
| Sagimet BiosciencesSGMT | <0.1% | $1m | 166,667 | New |
| Wave Life SciencesWVE | <0.1% | $1m | 189,253 | Held |
| Aktis OncologyAKTS | <0.1% | $1m | 32,436 | New |
| Tyra BiosciencesTYRA | <0.1% | $1m | 32,267 | -84% |
| Bolt BiotherapeuticsBOLT | <0.1% | $530,226 | 137,721 | Held |
| NextCureNXTC | <0.1% | $356,246 | 222,654 | Held |
| ImageneBioIMA | <0.1% | $188,116 | 31,884 | Held |
| HeartflowHTFL | <0.1% | $149,018 | 5,079 | New |
Options (4)
- Ultragenyx PharmaceuticalRARE
- Type
- Call
- Value
- $17m
- Contracts
- 500,000
- Intuitive SurgicalISRG
- Type
- Call
- Value
- $16m
- Contracts
- 40,000
- Globus MedicalGMED
- Type
- Call
- Value
- $16m
- Contracts
- 200,000
- ExelixisEXEL
- Type
- Put
- Value
- $14m
- Contracts
- 254,200
| Company | Type | Value | Contracts |
|---|---|---|---|
| Ultragenyx PharmaceuticalRARE | Call | $17m | 500,000 |
| Intuitive SurgicalISRG | Call | $16m | 40,000 |
| Globus MedicalGMED | Call | $16m | 200,000 |
| ExelixisEXEL | Put | $14m | 254,200 |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 27.4% since 30 June 2025.
Where the money is
Health care94.1%
Other5.9%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.